Taking part in a clinical trial may be the best treatment choice for some MDS patients. Clinical trials are under way for all MDS-risk types. Today's standard treatments for cancer are based on earlier clinical trials. LLS continues to invest funds in MDS research.
Clinical trials can involve new drugs, new combinations of drugs or approved drugs being studied to treat patients in new ways such as new drug doses or new schedules to administer the drugs. Clinical trials are conducted worldwide under rigorous guidelines to help doctors find out whether new cancer treatments are safe and effective or better than the standard treatment.
Current MDS Research and Clinical Trials
Scientists are conducting research strategies and clinical trials that study treatment with combinations of drugs approved by the Food and Drug Administration and with therapies similar to those used for acute myeloid leukemia (AML). Some examples of drug and drug-combination studies under way include:
- azacitidine (Vidaza®) and its effectiveness as a maintenance therapy in improving response duration for patients who achieve a complete or partial remission after intensive therapy
- clofarabine (Clolar®) and its effectiveness with acute myeloid leukemia-type chemotherapy
- ON 01910.Na (Estybon®), a new drug being studied with intermediate-1, -2 or high-risk patients
- lonafarmib (Sarasar®) and tipifarnib (Zarnestra®) and their effectiveness on transfusion independence for patients who receive between one to eight platelet transfusions every four weeks
- valproic acid (Depakene®) and its effectiveness when combined with decitabine (Dacogen®)
- vorinostat (Zolinza®) and its effectiveness when combined with azacitidine (Vidaza®)